The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the ten-year forecast period. One of these novel therapies is Yescarta, the first chimeric antigen receptor ( CAR ) T-cell therapy; it is approved for relapsed/refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) and represents a significant milestone in NHL drug development. Offsetting this market growth will be the biosimilar erosion expected for rituximab, the patient-, and market-share leader in 2016 in the NHL space, and the generic erosion of Revlimid (and, to a lesser extent, bendamustine). Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Kinase inhibitors have changed the NHL treatment algorithm since their recent approval. Which other kinase inhibitors are most promising in NHL , and what patient populations will they target? What will be their impact on the NHL market?
Rituxan/MabThera is widely used in all NHL drug-treated populations and garners significant sales. How will market share for rituximab change over our ten-year forecast period as a result of biosimilars? Will Gazyva/Gazyvaro achieve the same status as Rituxan/MabThera within the NHL space and thus minimize the impact of biosimilar erosion of branded rituximab?
The NHL therapymarket will experience robust growth through 2026. What factors are driving this growth? Which drug class will dominate the treatment of NHL ? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with experts and 211 country-specific surveys with hematologist-oncologists treating NHL .
Epidemiology: Diagnosed incidence of follicular lymphoma ( FL ) (including transformed FL ), chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL / SLL ), DLBCL , and mantle cell lymphoma ( MCL ).
Population segments in market forecast: First line, second line, and third line for FL , CLL / SLL , DLBCL , and MCL .
Emerging therapies: Phase I and II: 38 drugs; Phase III: 13 drugs; preregistration: 0 drugs; registered: 3 drugs.